|
Mesothelioma Articles
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma
2002
Mendes R, O'Brien ME, Mitra A, Norton A, Gregory RK, Padhani AR, Bromelow KV, Winkley AR, Ashley S, Smith IE, Souberbielle BE.
Lung Unit, Department of Haematology, The Royal Marsden Hospital NHS Trust, Downs Road, Sutton, SM2 5PT, UK.
The objectives of this study were to determine the toxicity of intratumoural/intrapleural SRL172 in addition to intradermal SRL172 and standard chemotherapy (mitomycin-C, vinblastine and cisplatin) in patients with malignant mesothelioma. Patients received chemotherapy (mitomycin-C: 8 mg m(-2), vinblastine: 6 mg m(-2), cisplatin 50 mg m(-2)) on a 3-weekly basis for up to six courses. IP SRL172 injections were given 3-weekly prior to chemotherapy and escalated in groups of three patients from 1 microg to 1 mg bacilli in 10-fold increments. Patients were also given ID SRL172 at a dose of 1 mg bacilli 4-weekly. Patients were assessed for toxicity after each course of chemotherapy and for response by CT imaging. Immuno-haematological parameters were analyzed pre-treatment and 1 month after completion of treatment. There was no dose limiting toxicity with IP SRL172 although there was greater toxicity at the highest dose (n=13). There were six out of 16 partial responses (37.5%). Haemato-immunological parameters, measured in seven patients pre and post-therapy, revealed that response rate correlated with a decrease in platelet count and there was an increase in activation of natural killer cells and a decrease in the percentage of IL-4 producing T cells in all tested patients post-treatment. SRL172 can be given safely into tumour deposits and the pleural cavity in patients with malignant mesothelioma and we have established the dose for phase II testing. Copyright 2002 The Cancer Research Campaign
SOURCE: PMID: 11875694 [PubMed - indexed for MEDLINE]
| MIRG.org 1-888-802-6376 e-mail |  |
|
|
•
•
•
•
•
|
Mesothelioma Information
Resource Group, MIRG.org, tries to assist individuals and families in learning about mesothelioma and other asbestos related injuries. It is the aim of MIRG.org to provide an account of the disease mesothelioma, its causes, various treatment options and potential legal impact. To find out more about Mesothelioma and other asbestos related diseases, new medical advances, and clinical trials now available please use the links provided.
The information on this website is presented by the Mesothelioma Information Resource Group and is for informational purposes only.
No particular course of treatment is suggested. All persons are advised to consult with a medical doctor concerning treatment of
mesothelioma or any illness. Also, nothing on this website is intended to constitute legal advice by a lawyer or attorney. Note disclaimer.
|
